In Vitro Susceptibility of Colistin Against Multidrug Resistant Klebsiella Pneumoniae Clinical Isolates
暂无分享,去创建一个
[1] M. Thaller,et al. Fighting MDR-Klebsiella pneumoniae Infections by a Combined Host- and Pathogen-Directed Therapeutic Approach , 2022, Frontiers in Immunology.
[2] F. Shahcheraghi,et al. Comparative genome analysis of colistin-resistant OXA-48-producing Klebsiellapneumoniae clinical strains isolated from two Iranian hospitals , 2021, Annals of Clinical Microbiology and Antimicrobials.
[3] S. Acharya,et al. Molecular Epidemiological Surveillance of CTX-M-15-producing Klebsiella pneumoniae from the patients of a teaching hospital in Sindh, Pakistan. , 2021, F1000Research.
[4] K. Prasad,et al. Genetic Characterisation of Colistin Resistant Klebsiella pneumoniae Clinical Isolates From North India , 2021, Frontiers in Cellular and Infection Microbiology.
[5] M. Khurshid,et al. In-Vitro Assessment Of The Therapeutic Potential Of Polymyxins And Tigecycline Against Multidrugresistant Acinetobacter Isolates From Infected Wounds. , 2020, Journal of Ayub Medical College, Abbottabad : JAMC.
[6] I. Ghout,et al. Efficacy of generic meropenem products in combination with colistin in carbapenemase-producing Klebsiella pneumoniae experimental osteomyelitis. , 2020, International journal of antimicrobial agents.
[7] N. French,et al. Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis , 2020, Advances in Therapy.
[8] Yongjun Wu,et al. Klebsiella pneumoniae: an increasing threat to public health , 2020, Annals of Clinical Microbiology and Antimicrobials.
[9] Y. Doi,et al. Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019) , 2020, Emerging microbes & infections.
[10] M. Al-agamy,et al. Emergence of colistin resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli strains isolated from cancer patients , 2019, Annals of Clinical Microbiology and Antimicrobials.
[11] P. Nordmann,et al. Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae. , 2019, The Journal of antimicrobial chemotherapy.
[12] D. Nicolau,et al. Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007) , 2019, Infectious Diseases and Therapy.
[13] M. Bassetti,et al. Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control , 2018, Expert review of anti-infective therapy.
[14] Yang Wang,et al. Emergence of a novel mobile colistin resistance gene, mcr-8, in NDM-producing Klebsiella pneumoniae , 2018, Emerging Microbes & Infections.
[15] Jacqueline A. Keane,et al. Phylogenetic Analysis of Klebsiella pneumoniae from Hospitalized Children, Pakistan , 2017, Emerging infectious diseases.
[16] P. Srinivas,et al. Polymyxin Resistance in Gram-negative Pathogens , 2017, Current Infectious Disease Reports.
[17] P. Plésiat,et al. Resistance to polymyxins in Gram-negative organisms. , 2017, International journal of antimicrobial agents.
[18] E. Percivalle,et al. Colistin inhibits E. coli O157:H7 Shiga-like toxin release, binds endotoxins and protects Vero cells. , 2016, The new microbiologica.
[19] G. Daikos,et al. Klebsiella pneumoniae: Virulence, Biofilm and Antimicrobial Resistance. , 2017 .